$ cat ./records/gates-foundation-funds-microneedle-patch-for-needle-free-measles--2019.txt
Gates Foundation Funds Microneedle Patch for Needle-Free Measles-Rubella Vaccination Without Cold Chain
[RECORD.TXT] · cat --full
The Gates Foundation funded development of a dissolvable microneedle patch for combined measles-rubella vaccination, developed by Micron Biomedical and the Georgia Institute of Technology. The patch is applied to the skin like a bandage, delivering vaccine antigens through 100 microscopic tips that dissolve within minutes. Unlike injectable vaccines, the patch requires no needles, no trained injectors, and no cold chain — shelf-stable at room temperature for one year. Clinical trials in adults in The Gambia validated safety and immunogenicity, establishing proof of concept for patch delivery of live-attenuated viral vaccines.
Source: https://www.gatesfoundation.org/ideas/articles/vaccine-patch-eliminate-needles
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Awards Second $5 Million MenAfriNet Grant to Track Emerging Serogroup Shifts Across the Meningitis Belt
Next →
Target Malaria Conducts First Genetically Modified Mosquito Release in Africa in Burkina Faso
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.